- Home
- ALDX vs NTHI Comparison
ALDX vs NTHI Comparison
Compare ALDX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALDX | NTHI |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.9M | 114.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALDX | NTHI |
|---|---|---|
| Price | $1.59 | $3.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.7M | 65.4K |
| Earning Date | 05-01-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $3.01 |
| 52 Week High | $6.18 | $12.99 |
Technical Indicators
Market Signals| Indicator | ALDX | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 35.86 |
| Support Level | $1.49 | $3.01 |
| Resistance Level | $1.91 | $4.59 |
| Average True Range (ATR) | 0.14 | 0.38 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 9.58 | 25.55 |
Price Performance
Historical ComparisonAbout ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.